RESMED INC(RMD)— Stock Profile, AI Score & Financials
Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
RESMED INC (RMD) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RMD at 74.3/100 on a 32-signal composite quality model, placing it at rank #113 of 2,960 stocks — the top 5% of the AI-ranked universe. RMD scores in the top quartile across balance sheet strength (95.5), profitability (85.4), free cash flow (83.2). Shareholder dilution risk is elevated at 41.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), RESMED INC reports quarterly revenue of $1.5B, net income of $383.4M, an operating margin of 30.7%. Top institutional holders of RMD by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. RMD trades on the NYSE exchange and files with the SEC under CIK 943819. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RESMED INC directly from SEC EDGAR.
AI Quality Score
74.3/100
AI Rank
#113
Revenue
$1.5B
Net Income
$383.4M
Free Cash Flow
$403.5M
Operating Margin
30.7%
RMD key financials by period
RESMED INC reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2026
10-K
$5.7B
$1.5B
33.4%
FY 2025
10-K
$5.1B
$1.4B
32.8%
FY 2024
10-K
$4.7B
$1.0B
28.2%
FY 2023
10-K
$4.2B
$897.6M
26.8%
FY 2022
10-K
$3.6B
$779.4M
28.0%
FY 2021
10-K
$3.2B
$474.5M
28.3%
Institutions holding RMD
Institutional investors reporting a position in RESMED INC on SEC Form 13F.
AI-extracted from the 10-K filed 2026-08-13 — FY2026 (year ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
ResMed reported fiscal year 2026 revenue of $3.26B, driven by Sleep and Breathing Health segment growth and software expansion, while acquiring Noctrix and planning to divest MatrixCare.
Biggest Revenue Drivers
Sleep and Breathing Health$2.87B
Core business segment providing CPAP, bilevel, ventilation devices, masks and connected digital health solutions for OSA and respiratory disorders.
Biggest Revenue Drivers
Total revenue: $3.26B
Sleep and Breathing Health$2.87B
Core business segment providing CPAP, bilevel, ventilation devices, masks and connected digital health solutions for OSA and respiratory disorders.
Largest Expense Items
Cost of sales (including depreciation and amortization)
Manufacturing, procurement and delivery of devices, masks and software solutions.
Selling, general and administrative$1.16B
Sales, marketing, distribution and administrative support across global operations.
Margins: The filing discusses gross margin pressures from inflation, supply chain disruptions, and competitive bidding programs affecting reimbursement, while noting ongoing investments in R&D and digital health capabilities to support long-term growth.
Watch Items from the Filing
VirtuOx (acquired 2025) is under a five-year Corporate Integrity Agreement (CIA) through 2027 following a $3M settlement; any CIA breach could result in exclusion from federal healthcare programs.
Noctrix device (acquired June 2026) lacks national Medicare coverage determination; coverage decisions made case-by-case by Medicare contractors, creating reimbursement uncertainty.
MatrixCare business (representing ~12% of annual revenue) is being divested for $490M; transaction expected to close in Q1 FY2027, reflecting portfolio optimization toward core sleep and breathing health.
Global tariffs and supply chain constraints remain dynamic risks; company sources components from multiple countries and manufactures in Singapore, Australia, Malaysia, China, and U.S., with potential exposure to new or increased tariffs.
Competitive reintroduction of Philips flow generators (historically under consent decree) could reduce demand; temporary market window from Philips recall may diminish as Philips returns to market.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
